In summary, the results of our study inferred that PRNP(PrPC) is an immune-related prognostic biomarker and has the potential to serve as a prognostic indicator for CRC immunotherapy, while also promoting proliferation, migration, and invasion. The gene discussed is PRNP; the disease is colorectal carcinoma.